New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
08:08 EDTMNTAMomenta Pharma stills sees 2013 operating cash use about $90M
Momenta confirmed its guidance, previously provided in November, for total operating expenses, excluding stock-based compensation and net of collaborative revenues, of approximately $30M per quarter in 2013. For 2013, Momenta is projecting that its net cash usage will average approximately $20M-$24M per quarter for a total operating cash usage of approximately $90M.
News For MNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
15:02 EDTMNTAMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTMNTATeva Copaxone patents to be reconsidered by regulators, Bloomberg says
August 20, 2015
07:31 EDTMNTAMomenta shares offer 'significant opportunity,' says Bernstein
Bernstein analyst Ronny Gal sees a "significant opportunity" in shares of Momenta Pharmaceuticals over the next few months. Copaxone sales should prove durable as a competing approval is unlikely until mid-2016, Gal tells investors in a research note. The analyst sees limited share downside before year-end and raised his price target for the stock to $31. He keeps an Outperform rating on Momenta.
August 19, 2015
10:05 EDTMNTAHigh option volume stocks
High option volume stocks: MNTA TUR ITB CLR HILL DV AU XLNK AEO CYBR

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use